Nashville Biosciences recently worked with a clinical stage biotech to develop a synthetic control arm for its active single-arm clinical trial in a rare but deadly cancer. The goal was to identify a virtual cohort of subjects that matched the selection criteria for the company’s actual clinical trial. We then studied this cohort to measure how they responded to current standard of care treatments and the outcomes they achieved. Download the case study to read more about our approach and how it can impact clinical development.
Synthetic Control Arm to Boost Clinical Development
Improving Early-Stage Drug Discovery Process
Nashville Biosciences recently worked with Pfizer’s Target Sciences and Technologies group to explore genetic targets for treating a serious metabolic disease with greatly increasing prevalence. The goal was to leverage BioVU® to rapidly select disease and disease-protected subject cohorts with multiple long-term clinical risk factors, and then perform DNA sequencing to identify new variants or mutations to inform further drug R&D. Download the case study learn more about this unique study design and how we used BioVU® to improve the early-stage drug discovery process.
Early Stage Drug Target Prioritization
Nashville Biosciences recently worked with a top-twenty pharmaceutical company to prioritize 20 early stage targets. The goal was to identify potential new therapeutic indications that fit with the company’s disease area priorities by using phenome wide association studies (pheWAS™). A pheWAS™-driven portfolio prioritization is only possible with a resource like BioVU® that combines a large population of prospectively genotyped subjects with a rich set of EMR-derived clinical phenotypes. Download the case study to find out how we accomplished this to help build a better drug portfolio.